Hims & Hers Health, Inc. (HIMS)
FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown
Hims & Hers ( NYSE:HIMS ) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its compounded weight-loss drugs.
Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill
Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
HIMS is scaling a platform-led digital healthcare model with Labs, AI and YourBio Health, integrating diagnostics, data and care into one ecosystem.
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
Online telehealth company Hims & Hers stock fell Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as little as $49, significantly lower than the $149 Novo sells the branded pill for.
Novo Nordisk stock climbs out of hole on FDA chief's threat to block Hims and Hers pill
Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.
Hims & Hers' $49 weight-loss pill jolts everyone, except its stock
Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month introductory price. Its shares ended down anyway.
Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks
A new pill from Hims & Hers Health is rattling shares of leading weight-loss drugmakers.
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Hims And Hers Will Undercut Wegovy Pill With $49 Copy—Novo Stock Shudders
Online pharmaceutical retailer Hims and Hers announced Thursday it will release a much cheaper, compounded version of the Wegovy weight loss pill just over half a year after Novo Nordisk caused its stock to collapse by terminating their distribution agreement out of concern for its mass-compounding activities.
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $26.44, indicating a -2.4% shift from the previous trading day.
Hims & Hers: A Platform Strategy Pivot Driving Long-Term Value
While the market fixates on short-term product cycles, Hims & Hers (HIMS) is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. The introduction of "Labs" creates the data layer for continuous health optimization, deepening engagement and enabling increasingly precise, personalized care over time. Scale achieved from making healthcare accessible to millions helps the company drive down unit costs, lower prices, expand adoption, and create a self-reinforcing flywheel of growing reach, engagement, and long-term platform value.
